Cantor Fitzgerald Weighs in on ARTV FY2024 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a report issued on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($3.63) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $23.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.49) per share.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.24).

A number of other brokerages have also commented on ARTV. Wedbush reaffirmed an "outperform" rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday, August 30th. Jefferies Financial Group began coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a "buy" rating and a $21.00 target price on the stock. TD Cowen initiated coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a "buy" rating for the company. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Artiva Biotherapeutics currently has an average rating of "Buy" and an average price target of $21.25.

Artiva Biotherapeutics Stock Up 2.5 %

Shares of ARTV stock traded up $0.25 during trading hours on Monday, reaching $10.31. 45,277 shares of the company's stock were exchanged, compared to its average volume of 137,514. Artiva Biotherapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $17.31. The business's fifty day simple moving average is $12.53.

Institutional Trading of Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at about $42,000. MetLife Investment Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $135,000. Barclays PLC acquired a new position in Artiva Biotherapeutics during the third quarter worth $304,000. Charles Schwab Investment Management Inc. bought a new stake in Artiva Biotherapeutics during the third quarter worth $623,000. Finally, Acuta Capital Partners LLC acquired a new stake in Artiva Biotherapeutics in the third quarter valued at $680,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.